These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 21245097

  • 1. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR.
    Cancer Res; 2011 Feb 01; 71(3):1009-18. PubMed ID: 21245097
    [Abstract] [Full Text] [Related]

  • 2. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD.
    J Nucl Med; 2006 Jul 01; 47(7):1144-52. PubMed ID: 16818949
    [Abstract] [Full Text] [Related]

  • 3. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW.
    Nucl Med Biol; 2007 Feb 01; 34(2):185-93. PubMed ID: 17307126
    [Abstract] [Full Text] [Related]

  • 5. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE.
    J Nucl Med; 2009 Dec 01; 50(12):2017-24. PubMed ID: 19910427
    [Abstract] [Full Text] [Related]

  • 6. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR.
    Eur J Nucl Med Mol Imaging; 2007 Aug 01; 34(8):1198-208. PubMed ID: 17262215
    [Abstract] [Full Text] [Related]

  • 7. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer.
    Shi J, Liu Z, Jia B, Yu Z, Zhao H, Wang F.
    Amino Acids; 2010 Jun 01; 39(1):111-20. PubMed ID: 19941017
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites.
    Linder KE, Metcalfe E, Arunachalam T, Chen J, Eaton SM, Feng W, Fan H, Raju N, Cagnolini A, Lantry LE, Nunn AD, Swenson RE.
    Bioconjug Chem; 2009 Jun 01; 20(6):1171-8. PubMed ID: 19480415
    [Abstract] [Full Text] [Related]

  • 9. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
    Chen J, Linder KE, Cagnolini A, Metcalfe E, Raju N, Tweedle MF, Swenson RE.
    Appl Radiat Isot; 2008 Apr 01; 66(4):497-505. PubMed ID: 18178448
    [Abstract] [Full Text] [Related]

  • 10. Isolation of a 177Hf complex formed by beta-decay of a 177Lu-labeled radiotherapeutic compound and NMR structural elucidation of the ligand and its Lu and Hf complexes.
    Cagnolini A, D'Amelio N, Metcalfe E, Nguyen HD, Aime S, Swenson RE, Linder KE.
    Inorg Chem; 2009 Apr 06; 48(7):3114-24. PubMed ID: 19243162
    [Abstract] [Full Text] [Related]

  • 11. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A.
    Nucl Med Biol; 2005 Oct 06; 32(7):741-7. PubMed ID: 16243650
    [Abstract] [Full Text] [Related]

  • 12. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
    Liu IH, Chang CH, Ho CL, Chiu SP, Lee WC, Chang TJ, Chen LC, Wu YH, Chuang CH, Fu YK, Lee TW.
    Anticancer Res; 2010 Oct 06; 30(10):4039-48. PubMed ID: 21036718
    [Abstract] [Full Text] [Related]

  • 13. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW, Bijster M, Krenning EP, De Jong M.
    J Nucl Med; 2004 Jul 06; 45(7):1260-9. PubMed ID: 15235075
    [Abstract] [Full Text] [Related]

  • 14. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.
    J Nucl Med; 2009 Oct 06; 50(10):1700-8. PubMed ID: 19793735
    [Abstract] [Full Text] [Related]

  • 15. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA.
    Cagnolini A, Chen J, Ramos K, Skedzielewski TM, Lantry LE, Nunn AD, Swenson RE, Linder KE.
    Appl Radiat Isot; 2010 Dec 06; 68(12):2285-92. PubMed ID: 20638858
    [Abstract] [Full Text] [Related]

  • 16. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
    Miao Y, Fisher DR, Quinn TP.
    Nucl Med Biol; 2006 Aug 06; 33(6):723-33. PubMed ID: 16934691
    [Abstract] [Full Text] [Related]

  • 17. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model.
    Miao Y, Hoffman TJ, Quinn TP.
    Nucl Med Biol; 2005 Jul 06; 32(5):485-93. PubMed ID: 15982579
    [Abstract] [Full Text] [Related]

  • 18. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D, Balkin ER, Jia F, Ruthengael VC, Smith CJ, Lewis MR.
    Nucl Med Biol; 2015 Sep 06; 42(9):704-10. PubMed ID: 26081917
    [Abstract] [Full Text] [Related]

  • 19. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
    Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R.
    J Nucl Med; 2013 May 06; 54(5):762-9. PubMed ID: 23492884
    [Abstract] [Full Text] [Related]

  • 20. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee Sy, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Feb 06; 42(2):131-6. PubMed ID: 25457455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.